Life Sciences Archives - EverGlade

Life Sciences

BARDA Seeks Input on Medical Countermeasures for Drug-Resistant Fungal Infections

Leave a Comment / All Posts, BARDA, Life Sciences / By

Download the Solicitation The Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), has issued a Request for Information (RFI) to better understand the current development landscape for antifungal medical countermeasures. BARDA plays a central role in advancing […]

BARDA Seeks Input on Medical Countermeasures for Drug-Resistant Fungal Infections Read More »

BARDA Seeks Input on AI-Enabled Discovery of Broad-Spectrum Small-Molecule Filovirus Therapeutics

Leave a Comment / All Posts, BARDA, Life Sciences / By

Download the Solicitation The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), has issued a Request for Information (RFI) focused on AI-Enabled Discovery of Broad-Spectrum Small-Molecule Inhibitors for Filoviruses. Filoviruses, including Ebola virus (EBOV), Sudan virus

BARDA Seeks Input on AI-Enabled Discovery of Broad-Spectrum Small-Molecule Filovirus Therapeutics Read More »

DARPA Explores Universal Biomolecule Purification Platforms Through New MTO RFI

Leave a Comment / All Posts, DARPA, Emerging Technologies, Life Sciences / By

Download the Solicitation The Defense Advanced Research Projects Agency (DARPA), through its Microsystems Technology Office (MTO), has released Request for Information (RFI) DARPA-SN-26-66 focused on biomolecule purification technologies. The RFI seeks information on novel purification methods capable of enabling a universal platform for separating and recovering multiple large and complex molecules from complex biological feedstocks

DARPA Explores Universal Biomolecule Purification Platforms Through New MTO RFI Read More »

ARPA-H’s THEA Program Seeks Breakthrough Optic Nerve Imaging Technologies

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

Download the Solicitation The Advanced Research Projects Agency for Health (ARPA-H), through its Health Science Futures Mission Office, has released a Sources Sought notice titled “Novel and Enhanced Modalities for Optic Nerve Imaging” (ARPA-H-SS-26-157). This request is being issued in support of ARPA-H’s Transplantation of Human Eye Allografts (THEA) program, an ambitious initiative focused on

ARPA-H’s THEA Program Seeks Breakthrough Optic Nerve Imaging Technologies Read More »

ARPA-H’s HEARING Program Aims to Revolutionize Brain-Driven Hearing Restoration

Leave a Comment / All Posts, ARPA-H, Emerging Technologies, Life Sciences / By

The Advanced Research Projects Agency for Health (ARPA-H), through its Health Science Futures (HSF) Office, has released an Innovative Solutions Opening (ISO) for Hearing Enhancement through ARtificially Intelligent NeurotechnoloGy (HEARING), ARPA-H-SOL-26-154. The program seeks to fundamentally rethink hearing loss treatment by shifting the focus from the ear alone to the brain’s auditory cortex. ARPA-H estimates

ARPA-H’s HEARING Program Aims to Revolutionize Brain-Driven Hearing Restoration Read More »

ARPA-H Launches IGoR Program to Transform Biomedical Research Infrastructure

ARPA-H Launches IGoR Program to Transform Biomedical Research Infrastructure

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

ARPA-H-SOL-26-155 APPENDIX A: PROGRAM AND TECHNICAL DESCRIPTION The Advanced Research Projects Agency for Health (ARPA-H) has released the Intelligent Generator of Research (IGoR) Innovative Solutions Opening (ISO), a bold initiative designed to fundamentally transform how biomedical research is conducted. Managed through ARPA-H’s Proactive Health Office, the program seeks to address longstanding inefficiencies in scientific discovery

ARPA-H Launches IGoR Program to Transform Biomedical Research Infrastructure Read More »

DARPA’s RAPIID Program shelf stable blood analogs

DARPA’s RAPIID Program to Transform Trauma Care with Shelf-Stable Blood Analogs

Leave a Comment / DARPA, Emerging Technologies, Life Sciences / By

DARPA-SN-26-77 The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), has issued Special Notice DARPA-SN-26-77 to announce forthcoming areas of interest for the Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program. As part of DARPA’s broader mission to accelerate breakthrough technologies for national security, this initiative aims to address one of

DARPA’s RAPIID Program to Transform Trauma Care with Shelf-Stable Blood Analogs Read More »

ARPA-H TIGAR Biopreservation

ARPA-H TIGAR Opens a New Lane for Biopreservation Innovation

Leave a Comment / ARPA-H, Life Sciences / By

ARPA-H-SOL-26-144_TIGAR ISO ARPA-H’s new Technology InteGrator and AcceleratoR (TIGAR) Innovative Solutions Opening (ISO) is a tightly scoped opportunity for government contractors and their research partners to reshape how complex biologics, tissues, and organs are stored, transported, and deployed at scale. By seeding high-risk, high-impact biopreservation concepts, TIGAR aims to unlock temperature-flexible storage for increasingly large

ARPA-H TIGAR Opens a New Lane for Biopreservation Innovation Read More »

BARDA-BAA-advanced-medical-countermeasures

BARDA’s Modernized BAA: A New On-Ramp for Advanced Medical Countermeasure Development

Leave a Comment / BARDA, Life Sciences / By

BARDA_FY23 Modernized BAA Solicitation – Amendment 7 The Biomedical Advanced Research and Development Authority (BARDA) has released its modernized Broad Agency Announcement (BAA-23-100-SOL-00004, Amendment 7), creating a flexible, multi-year pathway for industry to partner with the U.S. Government on advanced medical countermeasures (MCMs) for CBRN, pandemic influenza, and emerging infectious disease threats to the U.S.

BARDA’s Modernized BAA: A New On-Ramp for Advanced Medical Countermeasure Development Read More »

BARDA RFI Neuromuscular Junction

BARDA’s RRPV RFI on NMJ Micro-Physiological Systems for BoNT Evaluation

Leave a Comment / BARDA, Life Sciences / By

RRPV_RFI_BoNT-NMJ RFI Final Post Overview of Solicitation The Rapid Response Partnership Vehicle (RRPV), on behalf of the Biomedical Advanced Research and Development Authority (BARDA), has released a Request for Information (RFI) focused on neuromuscular junction (NMJ) micro-physiological systems (MPS) for botulinum neurotoxin (BoNT) applications. Managed by Advanced Technology International (ATI), this RFI seeks to assess

BARDA’s RRPV RFI on NMJ Micro-Physiological Systems for BoNT Evaluation Read More »

BARDA RRPV RAPID Solicitation Rapid Antibody Production

BARDA’s RRPV 26-10-RAPID Solicitation for Rapid Antibody Production

Leave a Comment / All Posts, BARDA, Life Sciences / By

RRPV-26-10-RAPID The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a new Request for Project Proposals (RPP) to stand up U.S.-based rapid antibody and protein binder production platforms that can go from pathogen gene sequence to immunoassay-ready reagents within weeks instead of months. This is a targeted opportunity to position platform

BARDA’s RRPV 26-10-RAPID Solicitation for Rapid Antibody Production Read More »

BARDA RFI ARDS Prevention

BARDA RFI on Host-Directed Therapeutics for ARDS Prevention

Leave a Comment / BARDA, Life Sciences / By

Overview of Solicitation The Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, has released a Request for Information (RFI)/Sources Sought Notice (SSN) titled “Host Directed Therapeutics for the Prevention of Progression to ARDS.” This effort, in support of BARDA’s

BARDA RFI on Host-Directed Therapeutics for ARDS Prevention Read More »

Scroll to Top